GenMark Diagnostics

GenMark Diagnostics is a molecular diagnostics company focused on developing and commercializing its sensor detection technology. The Company’s electrochemical technology enables the detection of up to 72 distinct biomarkers in a single sample. Its XT-8 System has received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular diagnostic tests with a compact workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified deoxyribonucleic acid (DNA) sample, its XT-8 System produces results. The XT-8 System supports up to 24 test cartridges, which can be run independently, and are targeted for hospitals and reference laboratories. The Company is also developing its next-generation platform, the AD-8 System, to integrate DNA amplification with its sensor detection technology to enable technicians to place a minimally prepared patient sample into its test cartridge.

GenMark Diagnostics Inc. (NASDAQ: GNMK) may not be a household name, and most investors are not aware of it, with its market cap of just under $300 million.

Is GenMark Diagnostics Underappreciated in the COVID-19 Fight?

Investors need to pay close attention to GenMark (GNMK) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in GenMark (GNMK) Stock?

Allied Healthcare Products

Gilead Sciences

Hepion Pharmaceuticals Inc

Novartis

Regeneron Pharmaceuticals

The coronavirus pandemic has delivered a shock to our economy, and the severity will be dependent on whether the "curve is flattened".

Coronavirus Pandemic Requires Patient Investing And A Focused Portfolio

GenMark Diagnostics, Inc. (NASDAQ: GNMK) shares are trading sharply higher on Friday, after the company received FDA emergency use authorization for its ePlex SARS-CoV-2 test.

Why GenMark's Stock Is Trading Higher Today

GenMark Diagnostics Inc. (NASDAQ: GNMK) stock shot up on Friday after the company announced that the U.S.

Meet the Newest and Maybe Quickest Coronavirus Test

COVID-19 diagnosis in under two hours now available globally in hospitals on company’s ePlex System

GenMark Receives FDA Emergency Use Authorization for its ePlex® SARS-CoV-2 Test

Traders are bidding up the stock in response to the submission of a regulatory filing.

Here's Why GenMark Diagnostics Is Rising Today

Shares of GenMark Diagnostics Inc. GNMK, +7.47% rose 8% in trading on Wednesday after the company said it had submitted its COVID-19 test to the Food and Drug Administration for emergency use authorization.

GenMark's stock rises 8% as it seeks authorization to market its COVID-19 test

GenMark Diagnostics, Inc (NASDAQ: GNMK) shares are headed higher again following an update from the company regarding its COVID-19 diagnostics test.

GenMark Diagnostics Files For Emergency Use Authorization For COVID-19 Test

Co-Diagnostics

Inovio Pharmaceuticals

OPKO Health

It is worthwhile to keep an eye on stocks of companies that are engaged in the prevention, diagnosis and treatment of the disease.

4 Stocks to Gain the Most From the Coronavirus Outbreak

Investors appear to be taking profits after the stock soared earlier this week on news that the company began shipping its coronavirus test kits.

Why GenMark Diagnostics Stock Is Falling Today

Alpha Pro Tech

BioCryst Pharmaceuticals

These companies have different products related to the coronavirus outbreak but share one thing in common: Their stocks are all rising.

Why These 4 Coronavirus-Focused Stocks Are Soaring Today

GenMark Diagnostics, Inc. (GNMK) CEO Scott Mendel on Q4 2019 Results - Earnings Call Transcript

GenMark Diagnostics (GNMK) delivered earnings and revenue surprises of -6.25% and 0.24%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GenMark Diagnostics (GNMK) Reports Q4 Loss, Tops Revenue Estimates

CARLSBAD, Calif., March  02, 2020  (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the initial shipments of ePlex Research Use Only (RUO) test kits designed to detect the SARS-CoV-2 virus.  Initial RUO test kits were recently shipped to the company’s Hong Kong distributor, as well as several U.S. customers that have access to clinical samples.  GenMark plans to use this information to support submission of an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the ePlex SARS-CoV-2 test to address this developing global public health emergency. 

GenMark Diagnostics Announces Global Shipments of ePlex® RUO Test Kits Designed for SARS-CoV-2 Detection

GenMark Diagnostics (GNMK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GenMark Diagnostics (GNMK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Calavo Growers

eBay

HEICO

TeleNav

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Go Beyond Bargain Hunting: 5 Stocks With Rising P/E

GenMark Diagnostics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GenMark Diagnostics Enters Oversold Territory

CARLSBAD, Calif., Feb.  10, 2020  (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that Scott Mendel, Chief Operating Officer, has been appointed Interim President and Chief Executive Officer effective immediately. Hany Massarany has stepped down as President and CEO and as a member of the company’s Board of Directors, effective immediately. A search has commenced to identify a permanent CEO.

GenMark Diagnostics Announces CEO and Chairman Transition

CARLSBAD, Calif., Jan.  13, 2020  (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2019.

GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2019

GenMark shares have continued to slide despite continually outperforming each quarter (modestly), good ongoing system placements, and healthy trends in panel demand.

GenMark Diagnostics Still Not Getting A Lot Of Love

GenMark Diagnostics' (GNMK) CEO Hany Massarany on Q3 2019 Results - Earnings Call Transcript

GenMark Diagnostics (GNMK) delivered earnings and revenue surprises of -5.26% and 1.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

GenMark Diagnostics (GNMK) Reports Q3 Loss, Tops Revenue Estimates

GenMark Diagnostics, Inc. (GNMK) CEO Hany Massarany on Q2 2019 Results - Earnings Call Transcript

GenMark Diagnostics (GNMK) delivered earnings and revenue surprises of -9.52% and 2.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

News for GenMark Diagnostics Stock (GNMK)